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It is increasingly clear that microRNAs play a crucial role in tumorigenesis. Recently, emerging
evidence suggested that miR-26a is aberrantly expressed in tumor tissues. In our study, frequent
down-regulation of miR-26a was observed in 10 human bladder cancer tissues. Forced expression
of miR-26a in the bladder cancer cell line T24 inhibited cell proliferation and impaired cell motility.
High mobility group AT-hook 1 (HMGA1), a gene that modulates cell cycle transition and cell motil-
ity, was veriﬁed as a novel target of miR-26a in bladder cancer. These ﬁndings indicate an important
role for miR-26a in the molecular etiology of bladder cancer and implicate the potential application
of miR-26a in bladder cancer therapy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer is the leading urological malignancy in China [1].
Many established factors, such as smoking and poison exposure,
are believed to contribute to tumorigenesis and progression of
bladder cancer [2,3]. However, the exact underlying molecular
mechanisms of bladder tumorigenesis remain unclear [4]. Accu-
mulating data suggests aberrantly expression of microRNAs (miR-
NAs) is a common phenomena in bladder cancer and miRNAs can
be key players during bladder tumorigenesis [5]. miRNAs are small
non-coding RNAs that function as negative gene regulators [6].
They can induce gene repression through interaction with partly
complementary sequences in the 30 untranslated regions (30-UTR)
of target mRNA. Thus, miRNAs are involved in diverse cellular
functions, such as differentiation, proliferation, metabolism and
apoptosis [7].miR-26a was found to be down-regulated in bladder cancer in
recent microarray studies [8,9]. miR-26a, located in chromosome
3p22, a region with high frequency of loss of heterozigozity
(LOH) in cancer, has been proved to be a tumor suppressor [10–
15]. However, the role of miR-26a in cancer cells was still contro-
versial as it served as an oncogene in glioma [16], lung cancer [17]
and cholangiocarcinoma [18]. The exact role of miR-26a in bladder
cancer has not been documented.
In our current study, we found that down-regulation of miR-26a
was frequently observed in bladder cancer tissues and cell lines. In
addition, gain of function study showed that forced expression of
miR-26a in bladder cancer cell lines T24 could inhibit cell prolifer-
ation and cell motility via a novel mediator high mobility group
AT-hook 1 (HMGA1). These ﬁndings document a clearer under-
standing of the underlying mechanism by which miR-26a inhibits
bladder cancer.
2. Materials and methods
2.1. Reagents
miR-26a mimic (termed as miR-26a) and negative control du-
plex (termed as miR-Con) lacking signiﬁcant homology to all
Fig. 1. Quantitative analysis of miR-26a in bladder cancer tissues and cell lines. The
expression of miR-26a was normalized with U6 snRNA in real time RT-PCR analysis.
(A) The relative expression levels of miR-26a in individual 10 pairs of cancer tissue
were presented as the fold change of miR-26a referred to the corresponding normal
tissues. (B) The miR-26a levels in bladder cancer cell lines (5637, UM-UC-3 and T24)
were detected and compared with non-tumor urothelial cell line SV-HUC-1.
(⁄P < 0.05).
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tion study. The small interference RNA targeting human HMGA1
mRNA (designated as siHM) and the corresponding scramble se-
quence (termed as scramble) were designed as described before
[19]. All the RNA duplexes were chemically synthesized by Gene-
Pharma (Shanghai, China) and the sequences were listed in
Table S1.
2.2. Tissue samples
Ten paired bladder cancer tissues and adjacent non-tumor
bladder mucosal tissues were obtained from patients undergoing
radical cystectomy. The samples were collected between Jan
2011 and June 2011 at the First Afﬁliated Hospital of Medical
College, Zhejiang University (Hangzhou, PR China) after informed
consent and Ethics Committee’s approval. Tissue samples were
trimmed and cryopreserved in liquid nitrogen for miR-26a quan-
titative study. All the demographic and clinical pathologic data
are listed in Table S2. Additionally, a commercial tissue micro-
array bearing 31 pairs of bladder cancer and corresponding
non-tumor tissues were purchased from Shanghai Outdo Biotech
(product ID: OD-CT-urBla03-002) for HMGA1 expression pattern
analysis.
2.3. Cell culture and transfection
All the cell lines in our study were obtained from Shanghai
Institute of Cell Biology, Chinese Academy of Sciences. HEK 293T
was cultured in DMEM, while bladder cancer cell lines 5637,
UM-UC-3, T24 and non-tumor urothelial cell line SV-HUC-1 were
cultured in RPMI1640. The medium were supplemented with
10% heat-inactivated fetal bovine serum, penicillin (50 U/ml), and
streptomycin (50 lg/ml) under a humidiﬁed atmosphere of 5%
CO2 at 37 C. The day before transfection cells were plated to
approximately 60% conﬂuency in medium without antibiotics.
The transfection was performed using Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s
instructions.
2.4. RNA Isolation and real-time PCR
MicroRNA was extracted from frozen samples or cancer cells
using RNAiso for Small RNA (Takara, Japan). Total RNA from the
cells was isolated with RNAiso Plus (Takara, Japan). The RNA was
reverse transcribed with a PrimeScript RT reagent Kit (Takara, Ja-
pan). All the procedures were conducted in accordance with the
manufacturer’s instructions. The resulting cDNA was quantiﬁed
by RT-PCR using SYBR Premix Ex Taq (Takara, Japan). The relative
expression level of miR-26a and HMGA1 was calculated and quan-
tiﬁed with the 2DDCt method after normalization with reference
to expression of U6 small nuclear RNA and GAPDH, respectively.
The primers were listed in Table S1.
2.5. Immunohistochemistry (IHC) staning
IHC staining was performed as described previously [20].
Brieﬂy, tissue section was deparafﬁnized in xylene, hydrated with
graded ethanol and quenched for endogenous peroxidase activity
in 0.3% hydrogen peroxide. Epitope retrieval was performed in so-
dium citrate solution (pH 6.0) under microwave heating. Goat ser-
um was used for blocking. The slide was incubated with HMGA1
primary antibodies at 4 C for overninght and incubated with a
HRP-conjugated secondary antibody at room temperature for 1 h.
DAB was applied for color development, and dark brown was con-
sidered positive staining. The images were captured with Aperio
ScanScope systems. The Strength of positivity was semi-quantiﬁedby comprehensively considering staining intensity and the propor-
tion of positive cells.
2.6. Cell viability assay
Cells were plated in 96-well plate and after overnight incuba-
tion, the cells were treated with RNA duplex (miR-26a, miR-con,
siHM or Scramble) and/or plasmid (over-expression vector of
HMGA1 or empty vector). After incubated for 48 h, cell viability
was evaluated with cell-counting solution (WST-8, Dojindo Labo-
ratories, Tokyo, Japan) as described previously [21].
2.7. Cell migration and invasion assay
The 24-well Boyden chamber with 8 lm pore size polycarbon-
ate membrane (Corning, NY) was used to analyze the cell motility.
For invasion assay, the membrane was pre-coated with matrigel to
form a matrix barrier. Equal number of cells, transfected with RNA
duplex and/or plasmid for 48 h,were seeded on the upper chamber
with serum-free medium. Medium with 20% serum was added to
the lower chamber as a chemoattractant. To minimize the effect
of proliferation inhibition, 105 cells were added to upper chamber
and the membranes were harvested and ﬁxed within 12 h. The
membranes were stained with 0.1% crystal violet and ﬁve visual
ﬁelds of 200 magniﬁcation of each membrane were randomly se-
lected and counted for the cell numbers under a light microscope.
2.8. Cell cycle analysis by ﬂow cytometry
Cells were harvested 48 h following transfection and ﬁxed in
75% ethanol at 20 C. After overnight ﬁxation, cells were washed
with PBS twice and followed by RNase A and propidium iodide
(50 lg/ml) treatment for 30 min. Cell cycle analysis was performed
by BD LSRII Flow Cytometry System with FACSDiva software (BD
Bioscience, Franklin Lakes, USA). The data were processed by Mod-
Fit LT software package.
2.9. Protein extraction and Western blotting
Following the RNA duplex and/or plasmid treatment as de-
scribed above, the cells were harvested and lysed. The protein con-
centration in the each lysate was determined using the
bicinchoninic acid protein assay kit (Pierce Biotechnology, Rock-
ford, IL, USA). Equivalent quantities of protein were separated by
12% SDS–polyacrylamide gels and transferred to nitrocellulose
membranes. Membranes were blocked with 5% non-fat milk and
then incubated overnight with the appropriate primary antibody.
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horseradish peroxidase (HRP)-conjugated secondary antibody for
1 h. Bound secondary antibody was visualized using an enhanced
chemiluminescence (ECL) system (Pierce Biotechnology, Rockford,
IL). The primary antibodies used were: anti-GAPDH, anti-HMGA1
(Epitomics, Burlingame, CA).
2.10. Luciferase assays
To construct the luciferase reporter vectors, a wild-type 30-UTR
(untranslated region) fragment of Human HMGA1 containing puta-
tive binding sites for miR-26a was ampliﬁed from genomic DNA
(primer set in Table S1). The ampliﬁed fragment was inserted into
pmirGLO Dual-Luciferase miRNA Target Expression Vector (Prome-
ga, USA) within the SacI/SalI sites. The mutant 30-UTR, carrying a
mutated sequence in the seeding region of miR-26a, was mutated
(primer set in Table S1) with the MutanBest Kit (Takara, Japan) as
decribed previously [21]. Then, the mutated sequence was sub-
cloned into pmirGLO Dual-Luciferase Vector. Both insertions were
veriﬁed by sequencing.
HEK 293T cells plated in a 24-well plate were co-transfected
with 50 nM of either miR-26a mimic or miR-Con and 200 ng repor-
ter comprising wild-type or mutant 30-UTR. The relative luciferase
activity was measured by Dual-Luciferase Reporter Assay System
(Promega, USA) 48 h after transfection.
2.11. HMGA1 rescue experiments
The human HMGA1 complementary DNA lacking the 30-UTR
was ampliﬁed form cDNA sample (primer set in Table S1) and
was cloned into XhoI /HindIII sites of pIRES2-eGFP (Clontech,
USA, the over-expression clone of HMGA1 would be termed as
pHMGA1). miR-26a or miR-Con was co-transfected with pHMGA1
or the empty vector (pNull). The cells were collected 48 h after
transfection for subsequentWestern blotting veriﬁcation, cell cycle
analysis, cell viability assay and cell motility evaluation.Fig. 2. Cell viability, cell cycle distribution and cell motility in T24 cells were analyzed 48
group was lower than that of miR-Con transfected. miR-26a reduced the T24 cell viabilit
blocks G1-S entry (representative histograms were shown above. The indicated percentag
T24 cells (representative migration and invasion results at 200 were shown). (D) Quan
migration and invasion (⁄P < 0.05).2.12. Statistical analysis
All data were plotted as mean ± standard deviation (S.D.) of
three independent experiments. Differences between samples
were analyzed by t-tests. All tests were performed using GraphPad
Prism version 5 for Windows and difference was deemed statically
signiﬁcant at P < 0.05.
3. Results
3.1. miR-26a is down-regulated in bladder cancer
As indicated by the previous microarray analysis [8,9], miR-26a
was in a down-regulated expression pattern in human bladder
cancers compared with normal bladder tissue. To further validate
the expression pattern of miR-26a in human bladder cancer,
miR-26a expression levels in 10 pairs of human bladder cancer
tissues and adjacent normal tissues were quantiﬁed by RT-PCR.
Compared with their non-tumor counterparts, a signiﬁcant
down-regulation of miR-26a expression was observed in tumor tis-
sues (Fig. 1A). Moreover, eight out of 10 exhibited down-regulated
pattern, with ﬁve presented with more than 50% reduction
(Fig. 1A). Furthermore, all the tested bladder cancer cell lines pre-
sented with a similar miR-26a expression pattern when compared
with non-tumor urothelial cell line SV-HUC-1 (Fig. 1B). The result
hinted that miR-26a might be a potential tumor suppressor in hu-
man bladder cancers. T24 cell, with the lowest miR-26a expression
level, was assigned for the following gain of function study.
3.2. miR-26a suppresses T24 cell proliferation, and induces G1-phase
arrest
We next investigate whether miR-26a could function as a tu-
mor suppressor. The proliferation rates of T24 cells after transient
transfection of miR-26a were assessed by cell viability assay. Nota-
bly, miR-26a demonstrated a potent inhibitory effect in T24 cell. Ash post miR-26a transfection. (A) The relative cell viability of the miR-26a transfected
y by 24.7%. (B) miR-26a induced a signiﬁcant accumulation of cells in G1 phase and
es were the average of triplicate experiments). (C) miR-26a impaired the motility of
tiﬁcation of cell motility by cell counting indicated a signiﬁcant suppression of cell
Fig. 3. IHC analysis of HMGA1 expression pattern in tissue microarray. There were 31 pairs of tissue in total, and three pairs of tissue were excluded from further semi-
quantitative analysis, since no mucosal tissue was presented in the non-tumor tissue. (A) IHC staining of HMGA1 in array and representative pair of dots. (B) HMGA1 showed
in stronger positivity in 20 out of 28 cancer tissues (Cancer) while comparing with the paired non-tumor tissues (NT) (P < 0.01).
Fig. 4. Forced expression of miR-26a inhibited HMGA1. (A) The HMGA1 mRNA level
was signiﬁcantly reduced following treatment of T24 cells with miR-26a mimics
(⁄P < 0.05). (B) Western blot analysis showed reduction in HMGA1 protein.
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cell viability reduced by 24.7% (Fig. 2A). To further elucidate the
underlying mechanisms for miR-26a-mediated growth suppres-
sion, the cell cycle distribution after miR-26a treatment was mea-
sured by ﬂow cytometry. The cell cycle distribution analysis
showed a signiﬁcant accumulation of cells in the G1-phase
(Fig. 2B). These results indicated that miR-26a could inhibit blad-
der cancer cells growth via G1-phase arrest.
3.3. miR-26a impairs T24 cell motility
To further understand the function of miR-26a, we investigated
the potential impact of miR-26a on T24 cell motility. As indicated
by the transwell assay, forced expression of miR-26a decreased the
migration and invasion of T24 cells compared with the control
(Fig. 2C and D). miR-26a is therefore a negative regulator of migra-
tion and invasion of T24 cells.
3.4. HMGA1 is a key regulator in miR-26a mediated cell cycle arrest
and cell motility impairment
To identify downstream targets of miR-26a, bioinformatics
analysis was carried out using online algorithms. We found that
the 30-UTR of the HMGA1 mRNA contains a miR-26a-complemen-
tary binding site, which is conserved among species (Fig. 8A).
HMGA1, a putative target of miR-26a identiﬁed from MicroCosm
and TargetScan, was of particular interest since it used to be con-
sidered as a positive cell cycle regulator and cell motility [22,23].
Moreover, HMGA1 over-expression portends a poor outcome in
bladder cancer [24]. In our current study, we revealed that HMGA1was commonly over-expressed in bladder cancer tissues (Fig. 3).
With RT-PCR and western blot, we veriﬁed that over-expression
of miR-26a down-regulated HMGA1 post-transcriptionally
(Fig. 4). Meanwhile, whether the physiological function of HMGA1
was involved in miR-26a mediated tumor suppression effect was
evaluated via both loss of function and gain of function approach.
The knock-down of HMGA1 by RNAi technique (Fig. S1) yielded
the anticipated cell cycle arrest and cell motility impairment,
which phenocopied the effect of miR-26a over-expression
(Fig. 5). In parallel, co-transfection of pHMGA1 was applied to
abrogate the HMGA1 expression inhibition by miR-26a (Fig. 6A).
Forced HMGA1 expression partially, but signiﬁcantly, attenuated
the G1-phase arrest by miR-26a (Fig. 6B and C) and promoted cell
viability (Fig. S2). Also, the cell motility was restored after
pHMGA1 transfection (Fig. 7). Thus, we conﬁrmed that HMGA1
was a key mediator of tumor suppression function of miR-26a in
bladder cancer.3.5. HMGA1 is a novel direct target of miR-26a
In order to identify that whether HMGA1 was a direct target of
miR-26a, the 144 bp sequence of the 30-UTR of HMGA1, containing
possible binding sites for miR-26a, was cloned into down-stream
of ﬁreﬂy luciferase of pmirGLO Dual-Luciferase miRNA Target
Expression Vector. Additional vector with mutated putative bind-
ing sites was also constructed (Fig. 7A). Co-transfected of either
miR-26a or miR-Con and reporter comprising wildtype (Wt) or
mutant (Mut) 30-UTR was performed. As expected, HEK 293T cells
transiently transfected with the Wt 30-UTR-reporter and miR-26a
exhibited a signiﬁcantly decrease in relative luciferase activity
comparing with miR-Con. However, the luciferase activity of the
reporter bearing Mut 30-UTR was unaffected by miR-26a
(Fig. 8B). Thus, we revealed that HMGA1 was a direct target of
miR-26a.4. Discussion
During the last decades, miRNAs have emerged as major regu-
lators involved in cancer development [25,26]. Globally aberrant
miRNA expression proﬁles of tumors have provided valuable
insights into the molecular pathways of oncogenesis. As one of
the most prominent miRNAs implicated in the tumorigenesis,
miR-26a has presented with a controversial role during tumor
progression. miR-26a was found to be reduced in numerous hu-
man cancers, including breast cancer [14], hepatic cell carcinoma
[11–13] and nasopharyngeal carcinoma [10,15]. EZH2, MTDH and
IL-6 were reported to be the targets which mediating tumor
suppression effect by miR-26a. However, in glioma, lung cancer
Fig. 5. Cell viability, cell cycle distribution and cell motility in T24 cells after HMGA1 knock-down. (A) HMGA1 knock-down caused a 18.6% cell viability reduction in T24 cells
at 48 h post siHM treatment. (B) HMGA1 knock-down induced G1 phase arrest (representative histograms were shown above. The indicated percentages were the average of
triplicate experiments). (C) HMGA1 knock-down impaired the motility of T24 cells (representative migration and invasion results at 200 were shown). (D) A signiﬁcant
suppression of cell migration and invasion was detected quantitatively (⁄P < 0.05).
Fig. 6. Forced expression of HMGA1 rescued miR-26a-mediated G1 phase arrest. (A) Either miR-26a or miR-Con were co-transfected with pNull or pHMGA1 into T24 cells.
Western blot analysis was then performed to conﬁrm the re-expression of HMGA1. (B and C) Forced expression of HMGA1 signiﬁcantly abrogated cell cycle arrest effect of
miR-26a (⁄P < 0.05). Representative histograms were shown in (C).
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mote cancer progression by targeting PTEN or GSK-3ß [16–18].
The diverse expression pattern and biological function might be
owing to unique genetic background in different type of cancer
cells. The exact role of miR-26a in bladder cancer was still quite
unclear. Thus, our current study intended to clarify the biological
function of miR-26a.
Indeed, our study demonstrated that miR-26a was frequently
down-regulated in bladder cancer tissues compared to normal
bladder tissues, even though the sample size was small and the
clinicopathological features of tissue samples were heterogeneous.
The expression pattern study in cell lines further strengthened the
conclusion that miR-26a was down-regulated in bladder cancer.Based on these ﬁndings, we hypothesized that miR-26a might be
a potential tumor suppressor in bladder cancer. As expected, the
forced expression of miR-26a inhibited proliferation of T24 cells.
Further cell cycle distribution analysis showed that increased cell
accumulation in G1-phase, and cell migration and invasion assay
demonstrated that miR-26a impaired cell motility.
To reveal the possible protein responsible for the cell cycle ar-
rest induced by miR-26a, we conducted computational search for
the target. Beside the validated targets of miR-26a, such as EZH2,
MTDH and IL-6, Li et al. [27] have veriﬁed that miR-26a-HMGA1
is one of the important pathway in anit-cancer effect of metformin
towards pancreatic cancer cells. Also, Palmieri et al. [28] revealed
that HMGA-targeting microRNAs, including miR-26a, had a critical
Figure 7. Forced expression of HMGA1 abrogated cell motility impairment by miR-26a. (A) Representative migration and invasion results at 200 were shown. (B)
Quantitative analysis revealed a signiﬁcant increase in cell migration and invasion after HMGA1 re-expression (⁄P < 0.05).
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identiﬁed that HMGA1 was frequently over-expressed in bladder
cancer tissue, which suggested an oncogenic role of this gene in
bladder cancer. Furthermore, we proved that HMGA1 was a poten-
tial target of miR-26a in bladder cancer. As indicated by PCR and
Western blot study, miR-26a could dramatically inhibit HMGA1
expression. Furthermore, luciferase assay conﬁrmed that miR-26a
suppressed HMGA1 by directly targeting to its 30-UTR.Fig. 8. Validation of HMGA1 as a direct target of miR-26a. (A) A schematic of the
computational predicted seed region in the 30-UTR of HMGA1 (conserved in human,
rhesus, dog, rat, mouse) was shown, as well as the mutated sequences used in this
study. (B) 293T cells were co-transfected with either miR-26a or miR-Con and
pmirGLO Dual-Luciferase miRNA Target Expression Vector comprising Wt or Mut
30-UTR of HMGA1. The relative ﬁreﬂy luciferase activity normalized with Renilla
luciferase was measured 48 h after transfection (⁄P < 0.05).HMGA1, a nuclear matrix protein with three AT-hook domains
that bind the minor groove of AT-rich DNA sequences, is highly ex-
pressed in virtually all aggressive human cancers and could serve
as a useful biomarker and therapeutic target in advanced malig-
nancies [29,30]. By inducing a conformational change in DNA or
modulating the molecular via protein–protein interaction [30],
HMGA1 would participate in various physiological processes, such
as proliferation, anchorage-independent cell growth, tumorigene-
sis, and metastatic progression [31]. HMGA1 was identiﬁed as a
key transcription factor enriched in poorly differentiated cancers,
including bladder [24]. In our study, we found knocking down of
HMGA1 could phenocopy the miR-26a effect on cell cycle and cell
motility, and forced expression of HMGA1 would partially rescued
cell from the inhibitory effect of miR-26a. These results together
with the over-expression pattern of HMGA1 in bladder cancer tis-
sue would highlight HMGA1 as crucial the bladder cancer
progression.
Meanwhile, we have to emphasize that HMGA1 is only one of
the targets involved in the miR-26a mediated tumor suppression,
since HMGA1 alone is not sufﬁcient to fully reverse the phenotype
change caused by miR-26a over-expression. There should be a
much more complex molecular network in the inhibitory effect
of miR-26a, while regarding multiple-targets characteristic of
microRNA [7]. Moreover, the functional interaction between miR-
26a and its host gene should also account for the inhibitory effect
[32].
In conclusion, our study suggests that miR-26a is a potential tu-
mor suppressor in bladder cancer. miR-26a, by targeting HMGA1,
can suppress proliferation and impair cell motility in bladder can-
cer cells. Restoration of miR-26a could be a vigorous therapeutic
strategy for bladder cancer therapy.
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